These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 17442078

  • 1. First case of typical Old World cutaneous leishmaniasis treated with miltefosine.
    Stojkovic M, Junghanss T, Krause E, Davidson RN.
    Int J Dermatol; 2007 Apr; 46(4):385-7. PubMed ID: 17442078
    [Abstract] [Full Text] [Related]

  • 2. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
    Calvopina M, Gomez EA, Sindermann H, Cooper PJ, Hashiguchi Y.
    Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
    [Abstract] [Full Text] [Related]

  • 3. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
    Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian AR, Kabir MJ, Nadim A.
    Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
    [Abstract] [Full Text] [Related]

  • 4. Cutaneous leishmaniasis with lymphadenopathy due to Leishmania donovani.
    Faber WR, Wonders J, Jensema AJ, Chocholova E, Kager PA.
    Clin Exp Dermatol; 2009 Jul; 34(5):e196-8. PubMed ID: 19077092
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [American cutaneous leishmaniasis: special features in diagnosis and therapy].
    Bormann G, William T, Schulz A, Marsch W, Gaber G.
    Dtsch Med Wochenschr; 2003 Oct 02; 128(40):2065-8. PubMed ID: 14523685
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Miltefosine for new world cutaneous leishmaniasis.
    Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H.
    Clin Infect Dis; 2004 May 01; 38(9):1266-72. PubMed ID: 15127339
    [Abstract] [Full Text] [Related]

  • 9. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
    Aguiar MG, Silva DL, Nunan FA, Nunan EA, Fernandes AP, Ferreira LA.
    J Antimicrob Chemother; 2009 Dec 01; 64(6):1234-40. PubMed ID: 19825819
    [Abstract] [Full Text] [Related]

  • 10. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
    Sundar S, Kumar K, Chakravarty J, Agrawal D, Agrawal S, Chhabra A, Singh V.
    Trans R Soc Trop Med Hyg; 2006 Jul 01; 100(7):698-700. PubMed ID: 16325873
    [Abstract] [Full Text] [Related]

  • 11. Treatment of diffuse cutaneous leishmaniasis with miltefosine: a case report.
    Zerpa O, Blanco B, Kannee C, Ulrich M, Sindermann H, Engel J, Convit J.
    Int J Dermatol; 2006 Jun 01; 45(6):751-3. PubMed ID: 16796642
    [Abstract] [Full Text] [Related]

  • 12. Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis.
    Ansari NA, Ramesh V, Salotra P.
    Trans R Soc Trop Med Hyg; 2008 Nov 01; 102(11):1160-2. PubMed ID: 18639311
    [Abstract] [Full Text] [Related]

  • 13. Case Report: Erysipeloid Cutaneous Leishmaniasis Treated with Oral Miltefosine.
    Parajuli N, Adhikary S, Karki A, Tiwari S.
    Am J Trop Med Hyg; 2020 Nov 23; 104(2):643-645. PubMed ID: 33236713
    [Abstract] [Full Text] [Related]

  • 14. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
    Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J.
    Clin Infect Dis; 2001 Oct 01; 33(7):E57-61. PubMed ID: 11528586
    [Abstract] [Full Text] [Related]

  • 15. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE.
    J Infect; 2006 Jul 01; 53(1):e25-7. PubMed ID: 16274744
    [Abstract] [Full Text] [Related]

  • 16. [Penile sporotrichoid cutaneous leishmaniasis].
    Masmoudi A, Boudaya S, Bouzid L, Frigui F, Meziou TJ, Akrout F, Turki H, Zahaf A.
    Bull Soc Pathol Exot; 2005 Dec 01; 98(5):380-1. PubMed ID: 16425718
    [Abstract] [Full Text] [Related]

  • 17. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB, Das P.
    Am J Trop Med Hyg; 2009 Mar 01; 80(3):336-8. PubMed ID: 19270277
    [Abstract] [Full Text] [Related]

  • 18. [Leishmaniasis with multiple cutaneous nodules].
    Stosiek N, Bogdan C, Solbach W, Hornstein OP.
    Dtsch Med Wochenschr; 1992 Nov 13; 117(46):1752-6. PubMed ID: 1425295
    [Abstract] [Full Text] [Related]

  • 19. Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.
    de Vries PJ, van der Meide WF, Godfried MH, Schallig HD, Dinant HJ, Faber WR.
    Trans R Soc Trop Med Hyg; 2006 Dec 13; 100(12):1183-6. PubMed ID: 16678871
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
    Godinho JL, Simas-Rodrigues C, Silva R, Ürmenyi TP, de Souza W, Rodrigues JC.
    Int J Antimicrob Agents; 2012 Apr 13; 39(4):326-31. PubMed ID: 22226653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.